2023年4月19日

2023年4月19日Phialogics临床生物科技公司是一家专门从事工程下一代生物平衡免疫反应的急性和慢性炎症。启动关闭600000€种子计划融资轮与高科技Grunderfonds资本将用于进一步发展Phialogics的领先候选人在临床前模型相比,目前的标准治疗和其他的研究方法。这是一个一步继续开发Phialogics的创新技术,为患者带来新的解决方案需要更好的治疗方案。巴塞尔,2023年4月19日——能够平衡免疫反应在急性和慢性炎症是很多患者患有自身免疫性疾病的关键。由于一个创新和专利技术,Phialogics带来一个新的回答这些未满足的医疗需求。这个概念是基于免疫球蛋白受体的有针对性的修改域(进口)调节免疫反应在炎性疾病。IgV介导receptor-ligand交互代表了一种新颖的生物制剂的重要来源。Phialogics导致分子复制内源性蛋白质相互作用有效地调节他们的目标受体的功能。到目前为止,只有这种独特的平台技术可以达到如此高的水平精度。目前的领先候选人转基因单一的进口有可能扩展到双特异性疗法实现选择性发炎组织和/或致病的免疫细胞。 This strategy has the potential to provide new solutions for patients with autoimmune diseases by rebalancing their overactive immune response in selected organs and tissue. For 2023, our goals are to further develop our lead candidate, completing proof of concept in preclinical models and comparing our lead to the standard of care. In addition, as a part of our new discovery project, we will expand our portfolio to novel bi-specific immune checkpoint modulators. This becomes possible thanks to the HTGF financing round. Dr. Andreas Ernst, Co-Founder & CEO of Phialogics We are excited to invest in the strong team of Phialogics and their innovative approach to modulate the immune response in inflammatory diseases. Their unique platform based on naturally occurring receptor-ligand interactions combined with a first class protein engineering expertise and deep knowledge in immunology has the potential to provide novel solutions for patients. We are excited to see the progress they will make with this pre-seed funding. Dr. Katharina Severin, Investment Manager atHigh-Tech Gründerfonds Team of Phialogics (Picture: Phialogics) About Phialogics AG Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics. About High-Tech Gründerfonds The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected more than 4.5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 160 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Media contact